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Novelty Statement 
 
Although evidence from RCT suggest that basal bolus insulin regimen is an effective insulin 
regimen, their effectiveness in real-world practice remains unclarified. 
 
This study is the first to evaluate the concordance between data derived from RCT and real 
world estimates of HbA1c and weight between basal bolus compared with a premixed insulin 
regimen and assess their interrelationship between patient and relevant clinical characteristics, 
as determinants of concordance. 
 
This study highlight specific discrepancies in the HbA1c reduction and weight change between 
real world outcomes versus RCT results. Greater baseline weight was associated with more 
favourable effect on weight outcome following premixed than basal bolus insulin regimen. 
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Abstract 
 
Aim: We evaluated the concordance between data derived from randomised controlled trials 
(RCT) and real-world estimates of HbA1c and weight change after 24 weeks of initiation of a 
basal-bolus compared with a premixed insulin regimen.  
Methods: Data were pooled from 8 RCTs after a systematic review examining BB (n = 1893) 
or PM (n = 1517) regimens. RW data were extracted from the UK primary care dataset for BB 
(n = 7,483) or PM (n=10,744). t-tests were used to compute the mean differences between 
HbA1c and weight from baseline, ANOVA was used to compare between the populations. 
Linear regression analyses were used to determine the predictors of this change  
Results: Both insulin regimens were associated with HbA1c reduction (-0.28% [real-world] 
and -1.4% [RCTs]) and weight gain (+0.27 kg [real-world]; +2.96kg [RCT]) but there were no 
significant differences between basal-bolus and premix. Discordances in the pattern of 
treatment response were, however, observed between real-world and RCT data for both insulin 
regimens. For any given baseline HbA1c, the change () HbA1c in RCT was greater than in 
RW conditions and at any baseline weight above ~60kg, RCT population showed overall 
weight gain in contrast to slight weight loss in the RW population. Lastly, for both populations, 
while greater baseline weight was associated with reduced response to treatment, the 
association was much steeper for the RCT compared with real-world population. Also, greater 
baseline weight was associated with more favourable effect on weight outcome following 
premixed and to a lesser extent with basal bolus insulin regimen. 
 
Conclusion: These results highlight discrepancies between real-world outcomes versus RCT 
results with respect to starting BB, (which is lower in real-world) or PM insulin regimens in 
people with Type 2 Diabetes. 
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Introduction 
 
Insulin therapy is essential for people with Type 2 diabetes (T2D), when diet and other glucose 
lowering therapy options have failed to achieve optimal HbA1c targets [1], to reduce the risks 
of long-term vascular complications [2,3]. Although the basal bolus and the premixed insulin 
are the two most widely used insulin regimens in T2D, there is no overall consensus regarding 
the most effective or optimal insulin regimen for people with T2D [4,5]. The basal-bolus 
regimen, which consists of multiple daily injections of rapid-acting insulin pre-prandially, in 
addition to a long-acting basal insulin, most closely mimics the pattern of insulin secretion [6], 
but the flexibility of this regimen is undermined by its complexity to count daily carbohydrate 
intake and adjust the insulin dose accordingly [7-9]. The premixed insulin regimen consists of 
a fixed ratio of rapid-acting insulin and intermediate insulin combined; thereby eliminating the 
need for patients to mix or adjust the insulin, themselves whilst also reducing the number of 
required daily injections. Although patients may find it easier to adhere to the premixed 
regimen [10] regular meal times and consistency in daily routine are sometimes necessary in 
order to gain maximum benefit and avoid the associated risk of hypoglycaemia.  
 
 Evidence from RCTs and meta-analyses have shown heterogeneous outcomes between basal-
bolus and premixed insulin regimens [11-13]. As such, the choice of the optimal insulin 
regimen continues to be debated [14]. Although RCTs meet regulatory and scientific standards, 
they do not necessarily reflect what happens in real world [15]. As such, the use of trial derived 
estimates of clinical outcomes when used to underpin guidelines, may present a biased view of 
the relative outcomes of treatments when used in routine practice. Failing to account for this 
discrepancy may lead to suboptimal patients’ outcomes and wasted healthcare resources.  
We therefore aim to evaluate the concordance between data derived from RCT, real world 
estimates of HbA1c, and weight reduction after 24 weeks of initiation of basal bolus compared 
with a premixed insulin regimen and assess their interrelationship between clinical 
characteristics and relevant clinical profiles as determinants of concordance.  
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Methods 
 
 Study Design and Data Sources 
Data were extracted from two sources- observational data from the UK primary care via The 
Health Improvement Network (THIN) and RCTs in people with T2D.  
 
The search strategy and terms used in the systematic selection of these trials have been fully 
described in our previous study [16]. However, we added an additional exclusion criterion in 
which trials lasting less than 6 months were excluded. These selected eight RCTs [11, 12, 17-
22] were randomised, double-bind parallel or crossover designs in which basal-bolus insulin 
regimen was compared to premix.  
In the observational population, we pooled data from the THIN database on people with T2D 
who initiated insulin therapy (either basal-bolus or premix). THIN is the UK computerised 
anonymised longitudinal primary care records with details of over 10.5 million patients derived 
from 532 general practices within the UK, shown to be demographically representative of the 
dynamics of the UK population [23]. We have previously published diabetes-related outcomes 
in routine clinical practice using this database. [24,25]  
 
Exposures and Outcomes: 
In both populations, the main exposure was insulin regimen- basal-bolus vs premix. The premix 
(biphasic) regimen intervention was defined as two or more injections of any brand of premixed 
insulin per day while the basal-bolus regimen was defined as any basal injection with at least 
a single bolus injection per day. These were specified in details in the treatment protocols of 
the RCTs, while in the observational data, these prescriptions were identified by their 
appropriate READ codes in the THIN database. The main outcomes were mean differences in 
glycaemic control (measured by HbA1c) and weight between the two population groups 
measured at 6 months and above. 
 
Covariates: 
For both populations (RCTs and Observational), data on baseline demographics and patients’ 
characteristics were obtained. Also, baseline and 6-month measurements of HbA1c and body 
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weight were obtained. Other important clinical measures as comorbidity states, medication use 
and other biochemical variables were obtained in the observational study population. 
  
Statistical Analyses 
For both the RCTs and observational data, the difference between HbA1c at baseline and at 6 
months (glycaemic control) was computed. Also, the difference in weight at baseline and 6 
months will be computed. Generally, descriptive statistics was used to summarise the baseline 
variables in both population groups. Missing data among the baseline covariates in the real-
world data were accounted for with multiple imputations using the chained equation model. 
Student t-test was used to determine the mean differences in HbA1c and weight between the 
insulin regimens at baseline and post 24 weeks. Linear regression analyses were conducted to 
identify the strongest predictors of glycaemic control and weigh change. Finally, we used 
ANOVA to compare the changes in HbA1c and weight between the insulin regimens and the 
study populations. Finally, we used ANOVA to compare the changes in HbA1c and weight 
between the insulin regimens and the study populations. 
 
All analyses were conducted using Stata Software, version 14 with statistical significance put 
at a p-level ≤ 0.05. 
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Results 
Baseline Characteristics 
In all populations, there were 21,637 participants with 3,410 in the RCT and 18,227 in the real 
world population. Among this, 9,376 received basal-bolus regimen, while 12,261 were on the 
premixed regimen.  
In the observational (THIN) database population group, the overall mean age was 61.5 
(SD13.8) years with the mean baseline HbA1c [72mmol/mol (8.7%) vs 72mmol/mol (8.7%)] 
and weight (90.7kg vs 92.1kg) in the premixed and basal-bolus groups respectively. Other 
important baseline variables in this group are summarised in Table 1. Weight, age, diastolic 
BP and comorbidity status differed significantly between both regimens at baseline. In the RCT 
population [9, 10, 15 -20], the mean HbA1c and weight were [74mmol/mol (8.9%) vs 
74mmol/mol (8.9%)] and (85.6kg vs 85.6kg) in the basal-bolus and premixed insulin regimens 
respectively. Other important baseline variables are summarised in Table 2. 
 
Change in HbA1c 
In the THIN database, there was a significant reduction from the baseline HbA1c of 
70mmol/mol (8.6%) to 67mmol/mol (8.3%) (mean diff = 0.28%; 95%CI: -0.30, – 0.27; p < 
0.0001) after 6 months. Both the premixed and basal-bolus insulin regimens showed similar 
reduction at 6 months.  There was better glycaemic control in the basal-bolus arm at 6 months 
of insulin initiation (mean diff = -0.08%; 95%CI: -0.11, -0.04; p = 0.0001)(Figure 1A).  
  
Similarly, the RCT population reported a significant improvement in glycaemic control, with 
a mean reduction in HbA1c of 1.4% (95% CI: –1.87,-0.92; p<0.0001) at 6 months from 
baseline. There was a significant reduction in HbA1c at 6 months 74mmol/mol (8.9%) vs 
58mmol/mol (7.5%); mean diff: 1.34%; 95%CI: –2.09, -0.6; p = 0.003) in the premixed group; 
as was in the basal-bolus regimen 74mmol/mol (8.9%) vs 57mmol/mol (7.4%); mean diff: 
1.44%; 95%CI: –2.20,-0.69; p = 0.0023). No significant difference in glycaemic control was 
observed between the two insulin regimens after adjustment for age and baseline weight.  
 
Change in Weight (Kg): 
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Overall, there was a significant increase in weight after 6 months in the THIN population 
(mean diff: 0.27; 95%CI: 0.18, 0.35; p < 0.0001), this represented an increase of 0.31kg 
(95%CI: 0.20, 0.42; p < 0.0001) in the premix arm vs 0.21kg (95%CI: 0.07, 0.34; p = 0.002) 
in the basal-bolus arm. Nonetheless, no significant difference in weight gain was recorded 
between these two (premixed vs basal-bolus) regimens at 6 months (Figure 1B).  
 
The RCT population recorded a significant increase in weight from 88.9kg at baseline to 91.9kg 
at 6 months (mean diff = 2.96kg; 95%CI: 2.05 – 3.88; p < 0.0001). In the premixed group, 
there was an increase in weight from 88.9kg to 91.2kg (mean diff: 2.26kg; 95%CI: 0.80, 3.71; 
p = 0.009) while the basal-bolus group had a greater increase of 88.8kg to 92.6kg (mean diff: 
3.67; 95%CI: 2.43 – 4.92; p = 0.0004). In spite of these, there was no significant difference 
between the changes recorded between the insulin regimens - premixed (2.26kg) vs basal-bolus 
(3.67kg) at 6 months. 
 
Predictors of response at baseline 
In the THIN data population, there was a weak correlation between baseline HbA1c and 
response to treatment ( HbA1c) because 20% of the variability in the change in HbA1c in this 
group was attributable to the HbA1c at baseline (r2 = 0.20; slope = −0.30; 95% CI −0.31, −0.2; 
p < 0.0001). There was a very little correlation due to age (slope = −0.004; p < 0.001), gender 
(slope = −0.05; p = 0.019), and duration of diabetes (slope = −0.003; p = 0.031). In contrast, in 
the RCT population, there was a strong correlation between baseline HbA1c and  HbA1c. 
88% of this variability in  HbA1c was attributable to the HbA1c at baseline (r2 = 0.88; slope 
= −1.43; 95% CI −1.77, −1.08; p < 0.0001). There was a non-significant correlation with age 
(slope = 0.04; p=0.941) and weight (slope = −0.02; p = 0.069).  
 
HbA1c reduction as a function of Baseline HbA1c in premixed and basal bolus regimen 
In Figure 2, comparison is made between these two insulin regimens in real-world and RCT 
conditions. These showed similar patterns of response to treatment as a function of baseline 
HbA1c i.e. greater response to treatment with higher baseline HbA1c values but steeper in the 
RCT population in for both regimens. At baseline HbA1c values of 64mmol/mol (8.0%) and 
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62mmol/mol (7.8%), both populations showed no change in HbA1c at 6 months, but below 
these, both populations reported an increase in HbA1c value at 6months, this being greater too 
in the RCT population. This same pattern was observed for basal-bolus. Thus for any given 
baseline HbA1c for both insulin regimens, the  HbA1c in RCT was greater than in real world 
conditions. No interaction with study populations was observed (RCT vs THIN, coefficient = 
0.003, p = 0.965).  
Weight change as a function of Baseline Weight in premixed and basal bolus regimen 
For changes in weight according to baseline weight, different response patterns were observed 
between different insulin regimens (Figure 3) in the RCT population. In the real-world 
population, there was a weak correlation between baseline weight and weight after 6 months.  
2% of the variability in weight change was attributable to the weight at baseline (r2 = 0.02; 
slope = −0.049; 95% CI −0.05, −0.04; p < 0.0001). This was independent of gender, age and 
duration of diabetes. In the RCT population, there was a slightly higher non-significant 
correlation between baseline weight and weight-change at 6 month as it shows that 49% the 
variability in weight change was attributable to the weight at baseline (r2 = 0.49; slope = 0.06; 
95% CI −0.04, 0.15; p=0.204), independent of age (slope = 0.07; p = 0.74). 
 The premixed group showed a slight negative correlation in real-world (r2=0.03; slope = −0.05; 
95% CI −0.06, −0.04; p < 0.0001), i.e. those with a baseline weight of more than 100kg 
experienced weight reduction, while those below 100kg at baseline, experienced weight-gain 
at 6 months (Figure 2a) but in the RCT population, this association was almost unity, (r2 = 
0.0005; slope = −0.003; 95% CI −0.17, 0.16; p = 0.962) – meaning that there was no change 
in weight at 6 months irrespective of baseline weight. For the basal-bolus treatment group, real 
world population showed a weak negative correlation (r2 = 0.02; slope = −0.05; 95% CI −0.05, 
−0.04; p < 0.0001): slight weight reduction as baseline weight increases. Conversely, the RCT 
group showed a positive correlation (r2 = 0.45; slope = 0.09; 95% CI −0.02, −0.19; p = 0.098), 
i.e. more weight-gain at 6 months as baseline weight increases. Taken together, at any baseline 
weight above 60kg, while the RCT group showed a weight gain, the real-world group observed 
a slight reduction in weight.  
HbA1c change as a function of Baseline Weight in premixed and basal bolus regimen 
The change in HbA1c as a function of baseline weight for premixed and basal bolus insulin 
regimens, showed that for both real world and RCT populations, greater baseline weight was 
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associated with reduced response to treatment. However, the association was much steeper for 
the RCT compared with real world population. Furthermore, for the premixed population, for 
any baseline weight, response to treatment was greater in the RCT population compared with 
real world conditions up until weight of approximately 110kg, above which, response to 
treatment was greater for real world populations.  Similarly, for the basal bolus insulin regimen, 
for any baseline weight, response to treatment was greater in the RCT population compared 
with real world conditions up until weight of approximately 110kg, above which, response to 
treatment was greater for real world populations up until 140kg weight, above which, response 
to treatment was slightly greater for real world populations  
 
 
  
Discussion: 
This analysis compared the relative HbA1c and weight outcomes of premixed insulin regimen 
or the basal bolus insulin regimen in people with type 2 diabetes in RCT vs in real-world 
conditions. Despite the significant difference in HbA1c found with basal-bolus in this study, 
its clinical relevance is unclear and no difference in HbA1c and weight was noted between 
insulin regimens for both real-world and RCT populations at 6months. Discordance in the 
pattern of treatment response was however observed between the populations for both insulin 
regimens. While the present analysis confirms the expected relationship between baseline 
HbA1c and HbA1c reduction with either a premixed or a basal-bolus insulin regimen, the 
strength of this relationship was considerably more apparent in the RCT population compared 
with real world conditions. We observed a negative association between weight-change at 
6months and baseline weight among patients receiving a premixed insulin regimen in both real-
world and RCT populations, i.e. as baseline weight increases, the weights in these populations 
at 6 months slightly reduced, and more marked in the real-world populations. However for 
patients receiving a basal-bolus insulin regimen, discordance in response was observed 
between real world and RCT populations, i.e. a negative association (reduction in weight at 
6months as baseline weight increases) in real-world conditions but a positive association 
(increase in weight at 6months as baseline weight increases) in the RCT population. Lastly, for 
both premixed and basal bolus insulin regimen, the expected relationship between baseline 
weight and response to insulin treatment was mainly apparent under RCT conditions.  
The cause of the discrepancies in the HbA1c and weight response with premixed insulin or a 
basal bolus insulin regimen in real world conditions compared with RCT is not clear. However, 
insulin regimen is associated with hypoglycaemia and weight gain[26, 27], with the latter often 
occurring only during the first months following insulin initiation; and an important difference 
between the premixed and the basal bolus insulin regimen is that the latter can be more 
demanding due to increased frequency of insulin injections and dose adjustments.   
Thus, it is tempting to speculate that the any discrepancies between real world and RCT is 
borne out of fear of hypoglycaemia, especially in the basal-bolus insulin regimen [26], weight 
gain [27], reduced compliance with a basal bolus insulin regimen or patients’ ambivalence to 
up-titrate insulin doses under real-world conditions due to lack of monitoring, patient-
education, or lack of rigid guidelines or protocols for patients to follow [28]. Fear of 
hypoglycaemia in real-world for example may explain the less apparent association between 
  
baseline HbA1c and response to treatment in real world conditions compared with RCT for 
both insulin regimens. Other likely possible explanations include the relatively younger age of 
the RCT population; and the higher rate of comorbidities and selection bias in the real-world 
population. 
Our observations that greater baseline weight was associated with more favourable effect on 
weight outcome following premixed and to a lesser extent with basal bolus insulin regimen 
should provide important reassurance that in routine clinical practice, meaningful reduction in 
HbA1c can be achieved without significant detrimental effect on weight. This observation was 
supported by findings from two other studies [29, 30]. In one study involving 155,917 patients 
who were recently initiated in insulin, Paul and colleagues reported that obese patients gain 
significantly less weight with insulin and that progressive reduction in body weight gain was 
observed with progressive increases in baseline BMI above 30 kg/m2, thought to be due to the 
use of less intensive insulin therapy [29]. Another reported a significant inverse association of 
baseline BMI with weight gain in a cohort of 2,179 patients with about nine years of median 
diabetes duration [30].  
 
Interestingly, the converse relationship between baseline weight and weight change was 
observed in our RCT cohort who received a basal bolus, but not the premixed insulin regimen. 
This implies an increase propensity to weight gain with basal bolus insulin regimen compared 
with premixed insulin in an RCT setting, supported by our findings from a systematic review 
and meta-analysis comparing basal bolus and the premixed insulin [31,32]. In addition, the 4-
T study reported that mean weight gain was higher in the prandial group than in either the 
biphasic group or the basal group [31].  
 
This analysis is subject to some limitations inherent to observational studies, including 
potential confounders such as compliance, indication bias, effects on ethnicity and differences 
in insulin regimens or titration protocols used across different areas in the UK. We attempted 
to minimize this by restricting the analysis only to patients who initiated a specific insulin 
regimen. Importantly, we do not have robust information on hypoglycaemic events that may 
limit the success of a given therapy, patient education programme, use and frequency of 
glucose self-monitoring, frequency of insulin dose adjustment and rules for self-adjustment of 
insulin dose or adjustment by feeling which have been shown to be important 
confounders.[8,31,33] With regards to the analysis of the RCT data, our previous meta-analysis 
  
of this area showed substantial heterogeneity was found in the meta-analysis on HbA1c change. 
This may be attributed to a number of confounding factors such as: poor study quality, small 
treatment groups, short study duration and different study designs. Lastly, we pooled trials and 
real world data using regular and analogue insulin because previous meta-analysis suggests 
similar HbA1c outcomes between the two types [28]. Despite these limitations, it is important 
to note that the emphasis of our study is a pragmatic approach to decision-making for initiation 
of insulin among patients who require insulin soon after diagnosis of diabetes in ‘real world’ 
clinical practice based on variables that are available to clinicians and to compare this with 
outcomes derived from RCT. This is because clinical trials involve strict adherence to treatment 
based on randomization to a given insulin regimen while in real world, the choice of insulin 
regimen involves the patient and takes other clinical and metabolic concerns into consideration. 
Additionally, unlike in RCTs which has a tight time schedule, treatment in real world setting 
is not limited by time. This confers a superior advantage to the evidence from real-word-
situation because people with diabetes need to deal with an insulin regimen not only for 6 to 
12 months like in RCTs but for a long, often life-long time. 
In summary this work showed that there is discordance in the pattern and magnitude of 
treatment response observed between real world and RCT populations between the two insulin 
regimens. The ‘blunting’ of the expected relationship between baseline HbA1c and the 
response to treatment with either a premixed or a basal bolus insulin regimens in real world 
and the reverse association between weight change and baseline weight among patients 
receiving the two insulin regimens between real world and RCT populations, emphasised the 
importance of patient-factors that would determine the potential success of one insulin regimen 
compared to another.  Choice of insulin regimen should therefore be individualised according 
to patients’ personal, social and clinical characteristics.
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Legend for Tables and Figures: 
 
Table 1 - Baseline Characteristics in real world (THIN Data) population 
Table 2 - Summary of baseline characteristics of the Randomised Clinical Trials 
 
Figure 1: 
Figures 1a and 1b show the mean difference in HbA1c (%) and weight (kg) between premix 
and basal-bolus insulin regimens in the RCT and real-world populations after 6 months of 
insulin initiation. 
 
Figure 2: 
Figures 2a and 2b show graphs depicting glycaemic control (measured by change in HbA1c) 
as a function of baseline HbA1c in type 2 diabetes population on insulin therapy after 24weeks 
and above. Comparison is made between the real world (THIN data) and the RCT populations 
in people on premix (A) and basal-bolus (B) insulin regimen. The interaction coefficient is, for 
(A) -0.30, p<0.0001; and (B) −1.43, p<0.0001. 
Figure 3: 
Figures 3a and 3b show graphs depicting change in weight as a function of baseline weight 
(kg) in type 2 diabetes population on insulin therapy after 24weeks and above. Comparison is 
made between the real world (THIN data) and the RCT populations in people on premix (A) 
and basal-bolus (B) insulin regimen. The interaction coefficient is, for (A) −0.049, p<0.0001; 
and (B) 0.06, p=0.204). 
 
 
 
 
  
Table 1 
 
Baseline variable 
Premix Insulin Basal-bolus Total p-value for 
differences (n = 10,744) (n = 7,483) (n = 18,227) 
Demographics     
Age (yrs), Mean (SD) 61.5 (12.7) 61.5 (14.9) 61.5 (13.8) 0.015 
Gender, No. (%)     
Male 5717 (53.2) 3978 (53.2) 9,695 (53.2) 
0.946 
Female 5027 (46.8) 3505 (46.8) 8,532 (46.8) 
Townsend deprivation, No(%)    
Least deprived 2024 (19.8) 1563 (21.7) 3,587 (20.6)  
2nd quintile 1989 (19.4) 1508 (21.0) 3,497 (20.1)  
3rd quintile 2229 (21.8) 1501 (20.9) 3,730 (21.4) <0.001 
4th quintile 2258 (22.0) 1505 (20.9) 3,763 (21.6)  
Most deprived 1742 (17.0) 1117 (15.5) 2,859 (16.4)  
Clinical Covariates, Mean (SD)    
HbA1c (%) 8.7 (1.8) 8.7 (1.9) 8.6 (1.8) 0.903 
BMI (kg/m2) 32.5 (6.8) 32.6 (6.9) 32.4 (6.9) 0.082 
Weight (Kg) 90.7 (18.5) 92.1(19.1) 90.8 (18.7) <0.0001 
Height (m) 1.7 (0.1) 1.7 (0.1) 1.7 (0.1) <0.0001 
SBP (mmHg) 136.4 (23.0) 136.2 (23.2) 136.4 (24.3) 0.122 
DBP (mmHg) 76.5 (10.7) 75.6 (10.9) 75.9 (10.9) <0.0001 
TC (mmol/l) 4.5 (1.3) 4.5 (1.3) 4.5 (1.3) 0.370 
HDL (mmol/l) 1.2 (0.5) 1.2 (0.5) 1.2 (0.4) 0.002 
LDL (mmol/l) 2.4 (1.1) 2.4 (1.1) 2.4 (1.01) 0.084 
Triglyceride (mmol/L) 2.1 (1.2) 2.0 (1.2) 2.0 (1.2) 0.188 
Albumin (g/L) 4.0 (0.4) 4.1 (0.4) 4.0 (0.4) 0.012 
eGFR (mls/min/1.73m2) 62.3 (21.0) 63.8 (21.5) 62.8 (21.8) <0.0001 
ACR (mg/mol) 5.8 (8.4) 5.9 (8.6) 5.8 (8.5) 0.830 
Diabetes duration (yrs) 3.9 (6.7) 4.8 (5.7) 4.3 (4.9) <0.0001 
Smoking status, No. (%)     
Non-smoker 5179 (48.2) 3682 (49.2) 8,809 (48.3)  
Current smoker 1498 (13.9) 1127 (15.1) 2,625 (14.4) 0.011 
Ex-smoker 4067 (37.9) 2674 (35.7) 6,793 (37.3)  
Alcohol status, No. (%)     
Non-drinker 3667 (34.1) 2249 (30.1) 5,916 (32.5)  
Current drinker 5840 (54.4) 4403 (58.8) 10,243 (56.2) <0.001 
Ex-drinker 1237 (10.5) 831 (11.1) 2,068 (11.3)  
BMI Categories, No. (%)     
≤ 24.9kg/m2 1451 (13.5) 1004 (13.4) 2,455 (13.5)  
25-29.9kg/m2 2587 (24.1) 1756 (23.5) 4,343 (23.8) 0.588 
≥ 30kg/m2 6706 (62.4) 4723 (63.1) 11,429 (62.7)  
Other GLTs, No. (%)     
      Metformin 9045 (84.2) 6548 (87.5) 15,593 (85.6) <0.001 
      Sulphonylurea 8004 (74.5) 5790 (77.4) 13,794 (75.7) <0.001 
      Thiazolidinedione 3009 (28.0) 2745 (36.7) 5,754 (31.6) <0.001 
      GLP-1ar 1034 (9.6) 909 (1.2) 1943 (10.7) <0.001 
       SGLT2 50 (0.5) 35 (0.5) 85 (0.5) 0.982 
       Glinides 422 (3.9) 368 (4.9) 790 (4.3) 0.001 
       DPP4i 1137 (10.6) 1432 (19.1) 2569 (14.1) <0.001 
Use of Medications, No. (%)     
Aspirin 10,647 (99.1) 7430 (99.3) 18,077 (99.2) 0.527 
Antihypertensive 9684 (92.6) 6252 (88.6) 15,936 (91.0) <0.001 
LLT 9588 (91.7) 6388 (90.5) 15,976 (91.2) 0.005 
Comorbidities, No. (%) c     
      MI 472 (4.4) 227 (3.0) 699 (3.8) <0.001 
CHD 3665 (34.1) 1795 (24.0) 5,460 (30.0) <0.001 
PAD 1649 (15.4) 759 (10.1) 2,408 (13.2) <0.001 
Heart Failure 1689 (15.7) 768 (10.3) 2,457 (13.5) <0.001 
  
Hypoglycaemia 2256 (21.0) 929 (12.4) 3,185 (17.5) <0.001 
CVA 1766 (16.4) 972 (13.0) 2,738 (15.0) <0.001 
     
Abbreviations: MET (metformin); SU (sulphonylurea); GLP-1RA (Glucagon-like peptide 1 receptor analogues); INS 
(insulin); BMI (body mass index); SBP (systolic blood pressure); DBP (diastolic blood pressure); HbA1c (haemoglobin 
A1c); HDL (high-density lipoprotein); LDL (low-density lipoprotein); TC (total cholesterol); GFR (glomerular 
filtration rate); LLT (lipid lowering therapy); PAD (peripheral arterial disease); CHD (coronary heart disease); ACR 
(albumin creatinine ratio); SD (standard deviation) 
Diabetes duration is time from first diagnosis of diabetes to date of commencement of insulin 
  
 
 
 
Table 2 
 
 
 
Study 
Baseline HbA1c 
mmol/mol[%] 
HbA1c at ≥24wks 
mmol/mol[%] 
Baseline     
Weight (kg) 
Weight (kg)      at 
≥24wks 
Age (yrs) 
Diabetes 
duration (yrs) 
Total number 
(N = 3410) 
Basal Premix Basal Premix Basal Premix Basal Premix Basal Premix Basal Premix Basal Premix 
Bowering et al, 2012 75 [9] 74 [8.9] 56 [7.3] 54 [7.1] 72.8 73.8 75.7 76.6 56.7 56.3 10 10.6 214 212 
Fritsche et al, 2010 70 [8.6] 69 [8.5] 56 [7.3] 61[7.7] 87 84.3 90.6 86.5 60.9 60.2 12.8 12.5 153 153 
Hirao et al, 2008 90 [10.4] 88 [10.2] 62 [7.8] 60 [7.6] 62.5 62.1 NR* NR 58.5 57.9 12.2 9.5 80 80 
Jain et al, 2010 78 [9.3] 80 [9.5] 58 [7.5] 60 [7.6] 78.8 78.2 82 81.3 58.9 59.9 12 11.4 242 242 
Levin et al, 2011 78 [9.3] 79 [9.4] 53 [7.0] 55 [7.2] 102.6 103.5 108.9 106.6 55.9 56.4 13.1 12.9 106 91 
Liebl et al, 2009 69 [8.5] 68 [8.4] 53 [7.0] 55 [7.2] NR NR NR NR 61.7 60.3 9.4 8.9 541 178 
Miser et al, 2010 (Arm A)  64 [8.0] 64 [8.0] 65 [8.1] 64 [8.0] 89.3 90.1 92.2 91.5 55.9 58.2 9.3 8.9 199 200 
                            (Arm B)  64 [8.0] 64 [8.0] 66 [8.2] 66 [8.2] 91.9 93.6 94.2 92.8 55.4 54.5 9.6 10 171 174 
Rosenstock et al, 2008 74 [8.9] 73 [8.8] 51[6.8] 53 [7.0] 99.8 99.1 104.3 103.1 55.4 54 11.2 10.9 187 187 
               
Mean Total 74 [8.9] 74 [8.9] 57 [7.4] 58 [7.5] 85.6 85.6 92.6 91.2 57.7 57.5 11.1 10.6 1893 1517 
NR = Not reported 
N = total number of all trial participants in these trials 
Diabetes duration is the duration of diabetes as at the commencement of the trial 
